ENDO USA, Inc. recalls
6 recalls filed under ENDO USA, Inc.. The most recent was published May 20, 2026.
-
Class II · 5 months ago
ENDO USA, Inc. Buprenorphine Hydrochloride, Injection, 0.3mg/mL recall: Crystallization; identified as Buprenorphine free base
Crystallization; identified as Buprenorphine free base
-
Class III · 12 months ago
Endo USA, Inc. Everolimus tablets 5mg, 28 tablets recall: Failed Impurities/Degradation Specifications: Out of specification
Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.
-
Class III · 12 months ago
Endo USA, Inc. Everolimus tablets 10 mg, 28 tablets recall: Failed Impurities/Degradation Specifications: Out of specification
Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.
-
Class III · 12 months ago
Endo USA, Inc. Everolimus tablets 2.5 mg, 28 tablets recall: Failed Impurities/Degradation Specifications: Out of specification
Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.
-
Class III · 12 months ago
Endo USA, Inc. Everolimus tablets 7.5mg, 28 tablets recall: Failed Impurities/Degradation Specifications: Out of specification
Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.
-
Class III · 1+ years ago
Endo USA, Inc. Everolimus tablets 5mg, 28 tablets recall: Failed Impurities/Degradation Specifications: Out of specification
Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.
About this page
ENDO USA, Inc. appears here because a federal agency named it as the recalling firm or the brand on the label. A recall is not a judgement about everything the company sells — it covers only the lot codes and models listed in each notice.